Home › Alpha-1 Antitrypsin Deficiency › NCT07135427
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Genetic Variation in IgG as a Mechanism for Immune Deficiency and Exacerbations in AATD
Who can join
Ages 19 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adults who are heterozygous for a SERPINA1 Z allele * Have either had no COPD exacerbations or 2 or more exacerbations in the previous year * Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine in the past Exclusion Criteria: * Received a pneumococcal conjugate vaccine within the past 5 years * Known allergy, severe adverse reaction, or other sensitivity to pneumococcal conjugate vaccines
About the study
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.
To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
What is being tested
- 20-valent pneumococcal conjugate vaccine (biological)
Sponsor: University of Alabama at Birmingham · Participants: 30 · Started: Sep 3, 2025
Contact the study team
- David LaFon, MD · Phone: 2059343411
Official record on ClinicalTrials.gov — NCT07135427
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.